Skip to Content

Lysodren (mitotane) Disease Interactions

There are 5 disease interactions with Lysodren (mitotane):

Major

Mitotane (Includes Lysodren) ↔ adrenal insufficiency

Severe Potential Hazard, Moderate plausibility. Applies to: Infection - Bacterial/Fungal/Protozoal/Viral, Shock

Mitotane inhibits production of corticosteroids and alters extra-adrenal metabolism of endogenous and exogenous steroids. All patients treated with mitotane should be instructed to immediately report signs and symptoms of infection or other illnesses. Therapy with mitotane should be withheld immediately following shock or severe trauma or infection. Exogenous steroids should be administered since the suppressed adrenal may not immediately begin to secrete steroids.

References

  1. "Product Information. Lysodren (mitotane)." Bristol-Myers Squibb, Princeton, NJ.
  2. Robinson BG, Hales IB, Henniker AJ, Ho K, Luttrell BM, Smee IR, Stiel JN "The effect of o,p'-DDD on adrenal steroid replacement therapy requirements." Clin Endocrinol (Oxf) 27 (1987): 437-44
Moderate

Mitotane (Includes Lysodren) ↔ depression

Moderate Potential Hazard, Moderate plausibility. Applies to: Depression

Symptoms of depression consisting of lethargy and somnolence have been reported during mitotane therapy. Therapy with mitotane should be administered cautiously to patients with or predisposed to depression. Clinical monitoring of psychological behavior is recommended.

References

  1. "Product Information. Lysodren (mitotane)." Bristol-Myers Squibb, Princeton, NJ.
Moderate

Mitotane (Includes Lysodren) ↔ liver dysfunction

Moderate Potential Hazard, High plausibility. Applies to: Liver Disease

Mitotane is primarily metabolized by the liver. Metabolism and therapeutic activity may be altered in patients with hepatic impairment. Therapy with mitotane should be administered cautiously in patients with hepatic impairment. Clinical monitoring of hepatic function is recommended.

References

  1. "Product Information. Lysodren (mitotane)." Bristol-Myers Squibb, Princeton, NJ.
Moderate

Mitotane (Includes Lysodren) ↔ neurologic disorder

Moderate Potential Hazard, High plausibility. Applies to: Neurologic Disorder

Unspecified brain damage and impairment of function have been reported during prolonged mitotane therapy. Therapy with mitotane should be administered cautiously to patients with neurologic impairment. Clinical monitoring of behavior and neurological function is recommended when continuous mitotane therapy exceeds two years.

References

  1. Hogan TF, Citrin DL, Johnson BM, Nakamura S, Davis TE, Borden EC "o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement." Cancer 42 (1978): 2177-81
  2. Lanser JB, van Seters AP, Moolenaar AJ, Haak HR, Bollen EL "Neuropsychologic and neurologic side effects of mitotane and reversibility of symptoms." J Clin Oncol 10 (1992): 1504
  3. "Product Information. Lysodren (mitotane)." Bristol-Myers Squibb, Princeton, NJ.
Moderate

Mitotane (Includes Lysodren) ↔ perimenopause

Moderate Potential Hazard, Moderate plausibility. Applies to: Menopausal Disorder

Ovarian macrocysts, often bilateral and multiple, have been reported in premenopausal patients receiving mitotane which might lead to adnexal torsion and hemorrhagic cyst rupture. It is recommended to use care when using this agent in premenopausal patients and to seek medical care if they experience gynecological symptoms such as vaginal bleeding and/or pelvic pain.

Lysodren (mitotane) drug interactions

There are 331 drug interactions with Lysodren (mitotane)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide